Novo Nordisk
NYSE:NVOPharmaBagsværd, Denmark, Denmark · Est. 1923 · 48,500 employees
Novo Nordisk is a global healthcare company specializing in diabetes care, obesity management, and other chronic diseases with a focus on insulin and GLP-1 receptor agonists.
30
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
34
Indications↗
Distinct diseases across all programs
1,381
Clinical Trials↗
All sponsored trials (all statuses)
75
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
30 drugs in development
Approved1
Phase 312
Phase 23
Phase 113
Preclinical7
By Therapeutic Area
top 6
Metabolic & Endocrine
1640%
Cardiovascular
513%
Hematology
513%
Nephrology
25%
Gastroenterology
13%
Rare Disease
13%
R&D Momentum
95/100
Pipeline Velocity
80/100
Trial Completion Rate
95/100
Pipeline Concentration
26/100
Pipeline Freshness
82/100
Strategic Signals
- ↗Active in Nephrology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 5, 2026
Terminated
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD
Nov 3, 2026
Completed
Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes
Oct 29, 2026
Recruiting
A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Oct 29, 2026
Recruiting
A Multinational, Open-label Study to Investigate Efficacy and Safety of Denecimig (Mim8) in Adults With Acquired Haemophilia A
Oct 29, 2026
No longer available
Concizumab Compassionate Use Programme for Patients With Congenital Haemophilia
Oct 27, 2026
Recruiting
A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administrations of NNC0642-1895 in Healthy Adults
Oct 27, 2026
Active, not recruiting
A Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic Hyperuricemia
Oct 23, 2026
Completed
A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Children With Growth Hormone Deficiency
3 more events
Oct 22, 2026TrialCLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Oct 20, 2026TrialTolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study
Oct 20, 2026TrialEfficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes
Details
Company Info
Company Overview
$550.0B
Mkt Cap
$21.4B
Revenue
—
Cash
CEOLars Fruergaard Jørgensen
Founded1923
Employees48,500
HQBagsværd, Denmark, Denmark
ExchangeNYSE:NVO
Websitenovonordisk.com
LinkedInCompany Page
Therapeutic Focus
Metabolic & EndocrineOtherCardiovascularGastroenterologyOncologyMusculoskeletalPsychiatryInfectious DiseaseRespiratoryHematologyNeurologyRare DiseaseOphthalmologyNephrologyImmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(5 drugs)
—
1
1
3
—
Cardiovascular(5 drugs)
Gastroenterology(1 drug)
—
1
—
—
—
Gastroenterology(1 drug)
Hematology(5 drugs)
—
2
—
3
—
Hematology(5 drugs)
Metabolic & Endocrine(16 drugs)
3
8
1
5
1
Metabolic & Endocrine(16 drugs)
Nephrology(2 drugs)
—
1
1
—
—
Nephrology(2 drugs)
Rare Disease(1 drug)
1
—
—
—
—
Rare Disease(1 drug)
Unknown / Other(10 drugs)
5
1
2
4
—
Unknown / Other(10 drugs)
Regulatory
Regulatory Timeline
20203 events
FDANov 20
Victoza — VICTOZA
Application NDA022341
FDAAug 5
Victoza — VICTOZA
Application NDA022341
FDAMar 9
Norditropin — NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN
Application BLA021148
20211 event
FDAJun 4
Ozempic — WEGOVY
Application NDA215256 (NDA)
20223 events
FDANov 30
Estrace — ESTRACE
Application ANDA086069
FDAJun 10
Victoza — VICTOZA
Application NDA022341
FDAJun 10
Victoza — VICTOZA
Application NDA022341
20232 events
FDASep 29
Rivfloza — RIVFLOZA
Application NDA215842 (NDA)
FDAJul 5
Victoza — VICTOZA
Application NDA022341
20244 events
FDADec 20
ALHEMO — ALHEMO
Application BLA761315 (BLA)
FDADec 9
Ozempic — RYBELSUS
Application NDA213051 (NDA)
FDANov 1
Victoza — VICTOZA
Application NDA022341
FDAFeb 15
Estrace — ESTRACE
Application ANDA086069
20257 events
FDADec 22
Ozempic — WEGOVY
Application NDA218316 (NDA)
FDAOct 14
Victoza — VICTOZA
Application NDA022341
FDAJul 9
Norditropin — NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN
Application BLA021148
FDAMay 28
Victoza — VICTOZA
Application NDA022341
FDAFeb 12
Victoza — VICTOZA
Application NDA022341
FDAJan 31
Norditropin — NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN
Application BLA021148
FDAJan 31
Norditropin — NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN
Application BLA021148
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)